Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 12;40(3):1390–1400. doi: 10.3892/or.2018.6568

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Lin et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Growth of CT26/tk-luc tumors in mice was monitored with bioluminescent imaging (BLI) and gamma scintigraphy. (A) The CT26/tk-luc tumor growth of a representative mouse in each group was assayed with BLI using the Xenogen IVIS50 system. (B) Gamma scintigraphy of CT26/tk-luc tumors in mice was performed at 24 h following 100 µCi/100 ml ¹³¹I-FIAU intravenous administration via the tail vein. The regions-of-interest (ROIs) of the tumors exhibited higher radioactivity compared with their normal counterparts, as illustrated by the tumor/muscle (T/M) ratios, which were the lowest in the combination group. a, control; b, TET 5 mg/kg × 12; c, TET 10 mg/kg × 6; d, TET 20 mg/kg × 3; e, IR (RT 3Gy ×6); f, TET 10 mg/kg × 6 + RT 3Gy × 6.

Figure 5. — Growth of CT26/tk-luc tumors in mice was monitored with bioluminescent imaging (BLI) and gamma scintigraphy. (A) The CT26/tk-luc tumor growth of a representative mouse in each group was assayed with BLI using the Xenogen IVIS50 system. (B) Gamma scintigraphy of CT26/tk-luc tumors in mice was performed at 24 h following 100 µCi/100 ml ¹³¹I-FIAU intravenous administration via the tail vein. The regions-of-interest (ROIs) of the tumors exhibited higher radioactivity compared with their normal counterparts, as illustrated by the tumor/muscle (T/M) ratios, which were the lowest in the combination group. a, control; b, TET 5 mg/kg × 12; c, TET 10 mg/kg × 6; d, TET 20 mg/kg × 3; e, IR (RT 3Gy ×6); f, TET 10 mg/kg × 6 + RT 3Gy × 6.